HymonBio is a high-tech enterprise focused on research and development, production and sales of innovative molecular diagnostic reagents and POCT-related products. The innovative “one-step method” effectively solves the cumbersome procedure of SARS-CoV-2 nucleic acid extraction. Now, the nucleic acid can be automatically released in a short time frame of 2 minutes, with fastest sample-to-results possible in only 35 minutes. Based on MoLock, nano-antibody molecular lock, technology and dual internal standard design, it achieves high sensitivity and specificity, and realizes full-process monitoring. So far, there has been no complaints from customers worldwide.
This COVID-19 test kit has passed quality evaluation of many clinical institutions, both in China and abroad, including: American Reference Laboratory, Kenya National Laboratory, Shanghai Clinical Testing Center, Jiangsu Medical Device Inspection Institute, etc., and has been approved by the US Food and Drug Administration EUA certification and the European Union CE certification, among many other national qualification certifications. It has been reported by more than 30 overseas media, and was cited by Dr. Stephan M. Hahn, current director of the FDA.
This product has been verified by authoritative organizations such as the Clinical Testing Center of the National Health Commission of China, the Department of Microbiology and Devices of the US FDA, the King’s College Hospital NHS Foundation of the United Kingdom, and the laboratory of the Hong Kong Polytechnic University affiliated to the Hong Kong Department of Health. It has been shown that it can also detect 100% of the variants of COVID-19, including but not limited to: Alpha, Beta, Gamma, Delta, and Omicron.
COVID-19 has erupted repeatedly throughout the world. Rapid and accurate detection is the key, and the market demand is huge. In addition to the SARS-CoV-2 Test Kit, HymonBio has a rich product pipeline, and has developed products covering rapid pathogen detection, early tumor screening, accurate tumor medication, cardiovascular drug guidance, POCT, and so on. The company’s new Respiratory Triplex Panel Test Kit is also unique; it adopts a leading 35-minute, one-step method to differentiate diagnoses and shunt management. The company has rich R&D experience and technical reserves in detection of infectious diseases, such as rapid HIV testing reagents, with a wide range of application prospects.
HymonBio’s ColoSafe™ Colorectal Cancer Test Kit uses non-invasive, liquid biopsy technology to simultaneously cover two types of gene methylation and mutation. Through accurate detection of colon-cancer-specific methylation markers and gene mutations in blood samples, it analyzes the risk of colorectal cancer, with a sensitivity of 96% and specificity of over 92%. The reagents provide a more convenient and effective means of painless early screening and auxiliary diagnosis of colon cancer, with a huge potential market.
With innovative technology and rich product lines, HymonBio is now inviting partnerships from agents and distributors for in vitro reagents and devices in China and abroad. The company will provide strong market support and operation guidance for partners with a broad space for cooperation for a win-win collaboration.
In order the deepen cooperation and show gratitude for support from many partners, HymonBio will hold a grand promotion during the holiday with unprecedented preferential strength. Agents and partners are welcomed to contact us for details.
Marketing & Sales
Tel:+ 86 21 6386 0095
Email：sales@hymonbio.com
David Lu
Tel:+ 86 13818258952
Email：lcl@hymonbio.com
Marketing & Sales: 16D, Hualong building, 333 south Suzhou Road, Huangpu District, Shanghai, China
Manufacturing: 52 Yingang Rd., Bldg 4, TC-BIOBAY Suzhou 215434, China
Post time: Dec-13-2021